Gastrointestinal Cancer
From the Journals
Interactive online module improved detection of Barrett’s esophagus neoplasia
Median detection rates for BORN rose by 30% after training.
News from the FDA/CDC
FDA: Safety signal emerged with higher dose of tofacitinib in RA study
The FDA is working with Pfizer to better understand how the signal affects patients and how the drug should be used, the agency said in a...
News
FDA approves combo Lonsurf for gastric and GEJ adenocarcinomas
FDA approval was based on a boost in overall survival demonstrated in the phase 3 TAGS trial.
From the Journals
Meta-analysis: Combo therapies best for neuroendocrine tumors
Also, various monotherapies outperform placebo, including everolimus, interferon, and sunitinib in pNETs; and somatostatin analogues in pNETs.
From the Journals
DAAs reduce mortality, cancer risk in HCV study
Large, prospective study showed direct-acting antivirals reduced mortality and cancer risk in chronic HCV-infected patients.
Conference Coverage
Pancreatic cancer expression signature is linked to chemoresistance
SAN FRANCISCO – Whole-genome and RNA sequencing of pancreatic cancers in the COMPASS trial has tied an RNA expression signature to poorer survival...
From the Journals
Laparoscopic distal gastrectomy safe alternative to open surgery
The mean number of retrieved lymph nodes was similar for the laparoscopic and open surgery groups.
From the Journals
Liver resection outcomes similar for robotic and open surgery
It’s still a matter of debate, however, whether robotic surgery has clear advantages over conventional laparoscopy for liver surgery.
From the Journals
Meta-analysis generally supports LI-RADS classification accuracy
But 13% of lesions classified as probably benign (LI-RADS2) were actually hepatocellular carcinomas.
Feature
Guardian angel or watchdog? Pills of capecitabine contain sensors
Whether that’s a good thing or bad thing depends on who you talk to, but patients do seem more likely to take their medications if a sensor is on...
Conference Coverage
Gastrectomy does not alter benefit of new oral chemo in gastric cancer
SAN FRANCISCO – In the phase 3 TAGS trial, the gastrectomy subgroup did have higher rates of grade 3 or 4 adverse events.